In the KEYNOTE-181 study, Pembrolizumab was found to be superior to chemotherapy in patients with advanced esophageal cancer, with PD-L1 ≥ 10 detected by Combined Positive Score (CPS) [10]. Here, CD274 is linked to esophageal cancer.